Press Releases

  • May 2, 2019

    Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®

    Allows 3rd Party Applications to Directly access SugarBEAT® CGM Data Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) —...

    April 23, 2019

    Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®

    Final step required prior to filing de novo application to the U.S. Food and Drug Administration Loughborough, England ,...

    April 18, 2019

    Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®

    Enhances Product Capabilities in Advance of CE Mark Approval April 16, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a...

    March 28, 2019

    Nemaura CEO Provides Update to Shareholders

    Announces SugarBEAT® Awaiting CE Mark Approval; On Track for FDA submission in Q2 2019 Loughborough, England, March 28, 2019...

    March 12, 2019

    Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region

    Loughborough, England , March 12, 2019 (GLOBE NEWSWIRE) — Loughborough, England – March 12, 2019 – Nemaura Medical, Inc....

    February 12, 2019

    Nemaura Reports Third Quarter 2018 Financial Results

    Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as...

    February 11, 2019

    Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development

    Dr. Schaebsdau to Advance European Launch of SugarBEAT® Continuous Glucose Monitor   Nemaura Preparing U.S. FDA 510(k) Submission  ...

    February 7, 2019

    Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm

    Loughborough, England – February 7, 2019 – Nemaura Medical Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the...

    January 17, 2019

    Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor

    Loughborough, England –Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com a medical technology company focused on the development of SugarBEAT® as...

    December 21, 2018

    Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval

    LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible...